Florkem 300 mg/ml Solution for Injection for Cattle and Pigs

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Florfenicol

Pieejams no:

Ceva Animal Health Ltd

ATĶ kods:

QJ01BA90

SNN (starptautisko nepatentēto nosaukumu):

Florfenicol

Zāļu forma:

Solution for injection

Receptes veids:

POM-V - Prescription Only Medicine – Veterinarian

Ārstniecības grupa:

Cattle, Pigs

Ārstniecības joma:

Antimicrobial

Autorizācija statuss:

Authorized

Autorizācija datums:

2009-08-25

Produkta apraksts

Revised: September 2022
AN: 01506/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Florkem 300 mg/ml solution for injection for cattle and pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Florfenicol ............................................. 300 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Colourless to yellow clear solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle and pigs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
CATTLE:
Treatment of respiratory tract infections due to _Mannheimia
haemolytica_, _Pasteurella _
_multocida _and_ Histophilus somni _susceptible to florfenicol.
PIGS:
Treatment of acute outbreaks of swine respiratory disease caused by
strains of
_Actinobacillus pleuropneumoniae_ and _Pasteurella multocida_
susceptible to florfenicol.
4.3
CONTRAINDICATIONS
Do not use in adult bulls or boars intended for breeding purposes.
Do not administer in cases of hypersensitivity to the active
ingredient or any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: September 2022
AN: 01506/2022
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Wipe the stopper before removing each dose. Use a dry, sterile needle
and syringe.
Do not use in piglets of less than 2 kg.
Under field conditions, approximately 30% of treated pigs presented
with pyrexia
(40°C) associated with either moderate depression or moderate
dyspnoea a week or
more after administration of the second dose.
Use of product should be based on susceptibility testing of the
bacteria isolated from
the animal. If this is not possible, therapy should be based on local
(regional, farm
level) epidemiological information about susceptibility of the target
bacteria.
Official national and regional antimicrobial policies should be taken
into account when
the product is used.
Use of the product deviating from the instructions given in the SPC
may